{'fraction_non_alphanumeric': 0.04888888888888889, 'fraction_numerical': 0.03428571428571429, 'mean_word_length': 4.947169811320754, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P06.02: Third trimester ultrasound screening in IVF pregnancies

Objectives: Pregnancies achieved through in vitro fertilisation (IVF) are associated with increased perinatal morbidity. The benefits of antenatal testing in this group are unknown. Our objective was to determine the incidence of abnormal ultrasound (US) findings in a cohort of women with IVF pregnancies. Methods: We conducted a prospective observational study evaluating our US protocol for IVF pregnancies which includes weekly BPPs starting at 36 weeks and growth US at 32 and 36 weeks. Records were reviewed from April 2017 – March 2019. Singleton gestations conceived with IVF were included. Women with an isolated IVF pregnancy were compared to those with an IVF pregnancy and a medical comorbidity*. Outcomes included detection of fetal growth restriction (FGR), large for gestational age (LGA), oligohydramnios, polyhydramnios or abnormal BPP (< 8/8). Results: A total of 272 women with IVF pregnancies received an US ≥ 32 weeks. Among women with an isolated IVF pregnancy (n = 205), 8 had FGR (3.9%), 9 had LGA (4.4%), 4 had oligohydramnios (2.0%), 14 had polyhydramnios (6.8%), and 10 had an abnormal BPP (4.9%). LGA was more common in IVF pregnancies with additional comorbidities (4.4% vs 16.4%; p = 0.003). Conclusions: In singleton IVF pregnancies, the detection rates of FGR, fluid abnormalities, and abnormal BPPs were similar between those with and without additional comorbidities. Perinatal outcome data is needed to determine possible benefit of antenatal testing in this cohort of women.